» Articles » PMID: 38043324

Use of Personal Care Product Mixtures and Incident Hormone-sensitive Cancers in the Sister Study: A U.S.-wide Prospective Cohort

Overview
Journal Environ Int
Date 2023 Dec 3
PMID 38043324
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Personal care products (PCPs), a source of endocrine-disrupting chemical exposure, may be associated with the risk of hormone-sensitive cancers. Few studies have investigated associations for PCP use with the incidence of hormone-sensitive cancers or considered the joint effect of multiple correlated PCPs. We examined associations between frequently used, or "everyday", PCPs and incident cancers of the breast, ovary, and uterus with a fucus on the joint effect of multiple product exposure.

Methods: Sister Study participants (n=49 899) self-reported frequency of use in the year before enrollment (2003-2009) for 41 PCPs. Using five-level frequency categories based on questionnaire options, hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for the associations between multiple PCP use and incident breast, ovarian, and uterine cancer using quantile-based g-computation with Cox proportional hazards regression as the underlying model. Multiple PCP use was examined using groupings (beauty, hygiene, and skincare products) determined by both a priori knowledge and Spearman correlation coefficients for co-occurring product use. Associations between individual PCPs and the three cancers were also examined using Cox proportional hazards models coupling with Benjamini-Hochberg procedure for multiple comparisons.

Results: Over an average of 11.6 years, 4 226 breast, 277 ovarian, and 403 uterine cancer cases were identified. Positive associations were observed between the hygiene mixture and ovarian cancer (HR=1.35, 95%CI=1.00, 1.83) and the beauty mixture with postmenopausal breast cancer (HR=1.08, 95%CI=1.01, 1.16). Additionally, we observed an inverse association between the skincare mixture and breast cancer (HR=0.91, 95%CI=0.83, 0.99). No significant associations were observed for individual products after corrected for multiple comparison.

Conclusions: Findings from this multi-product, joint-effect approach contribute to the growing body of evidence for associations between PCPs and breast cancer and provides novel information on ovarian and uterine cancer.

Citing Articles

Body dissatisfaction widens the racial disparities of Benzophenone-3, a chemical biomarker of personal care and consumer product usage.

Nguyen V, Zimmerman S, Colacino J, Jolliet O, Patel C medRxiv. 2024; .

PMID: 39252908 PMC: 11383470. DOI: 10.1101/2024.08.26.24312258.


Frequency of personal care product use among reproductive-aged Black individuals and associations with socio-demographic characteristics.

Taylor K, Co C, Gaston S, Jackson C, Harmon Q, Baird D J Expo Sci Environ Epidemiol. 2024; 34(4):659-669.

PMID: 38811800 PMC: 11303245. DOI: 10.1038/s41370-024-00690-x.


Personal Care Product Use during Puberty and Incident Breast Cancer among Black, Hispanic/Latina, and White Women in a Prospective US-Wide Cohort.

Goldberg M, Chang C, Ogunsina K, OBrien K, Taylor K, White A Environ Health Perspect. 2024; 132(2):27001.

PMID: 38306193 PMC: 10836586. DOI: 10.1289/EHP13882.

References
1.
Morch L, Skovlund C, Hannaford P, Iversen L, Fielding S, Lidegaard O . Contemporary Hormonal Contraception and the Risk of Breast Cancer. N Engl J Med. 2017; 377(23):2228-2239. DOI: 10.1056/NEJMoa1700732. View

2.
Lambe M, Hsieh C, Chan H, Ekbom A, Trichopoulos D, Adami H . Parity, age at first and last birth, and risk of breast cancer: a population-based study in Sweden. Breast Cancer Res Treat. 1996; 38(3):305-11. DOI: 10.1007/BF01806150. View

3.
OBrien K, DAloisio A, Shi M, Murphy J, Sandler D, Weinberg C . Perineal Talc Use, Douching, and the Risk of Uterine Cancer. Epidemiology. 2019; 30(6):845-852. PMC: 6779343. DOI: 10.1097/EDE.0000000000001078. View

4.
Wentzensen N, OBrien K . Talc, body powder, and ovarian cancer: A summary of the epidemiologic evidence. Gynecol Oncol. 2021; 163(1):199-208. DOI: 10.1016/j.ygyno.2021.07.032. View

5.
Tworoger S, Missmer S, Barbieri R, Willett W, Colditz G, Hankinson S . Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst. 2005; 97(8):595-602. DOI: 10.1093/jnci/dji099. View